Fort Washington Investment Advisors Inc. OH Acquires 53,617 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fort Washington Investment Advisors Inc. OH raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 376,047 shares of the biopharmaceutical company’s stock after acquiring an additional 53,617 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Gilead Sciences were worth $34,735,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Atomi Financial Group Inc. grew its holdings in shares of Gilead Sciences by 36.7% in the fourth quarter. Atomi Financial Group Inc. now owns 8,312 shares of the biopharmaceutical company’s stock worth $768,000 after purchasing an additional 2,231 shares during the last quarter. LifePlan Financial LLC boosted its position in Gilead Sciences by 9.2% in the 4th quarter. LifePlan Financial LLC now owns 5,987 shares of the biopharmaceutical company’s stock valued at $553,000 after buying an additional 504 shares during the period. Lmcg Investments LLC boosted its position in Gilead Sciences by 0.6% in the 4th quarter. Lmcg Investments LLC now owns 103,025 shares of the biopharmaceutical company’s stock valued at $9,516,000 after buying an additional 650 shares during the period. Brookmont Capital Management grew its stake in Gilead Sciences by 16.7% in the 4th quarter. Brookmont Capital Management now owns 51,083 shares of the biopharmaceutical company’s stock worth $4,719,000 after acquiring an additional 7,322 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in shares of Gilead Sciences by 1.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 540,220 shares of the biopharmaceutical company’s stock worth $49,900,000 after acquiring an additional 8,741 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research reports. Oppenheimer boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wolfe Research initiated coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $92.96 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a market cap of $115.85 billion, a PE ratio of 1,032.89, a P/E/G ratio of 1.29 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The business has a 50-day simple moving average of $91.65 and a two-hundred day simple moving average of $84.38.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock worth $42,130,461 in the last 90 days. Insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.